Trials / Completed
CompletedNCT02612649
Special Drug Use Surveillance of Irribow in Female Patients
Special Drug Use Surveillance of Irribow® Tablets and Irribow® OD Tablets in Female Patients
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 793 (actual)
- Sponsor
- Astellas Pharma Inc · Industry
- Sex
- Female
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The purpose of the survey is to evaluate the safety and efficacy of Irribow and Irribow OD Tablets in post-marketing medical practice and to examine the status of treatment compliance.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ramosetron | Oral |
Timeline
- Start date
- 2015-10-01
- Primary completion
- 2018-03-31
- Completion
- 2018-03-31
- First posted
- 2015-11-24
- Last updated
- 2024-10-21
Locations
34 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT02612649. Inclusion in this directory is not an endorsement.